Covishield Can Cause Rare Side Effect, Admits AstraZeneca
AstraZeneca has admitted in court documents for the first time that its Covid vaccine may lead to a rare side effect, according to media reports. It is noteworthy that AstraZeneca's vaccine was sold as Covishield in India in partnership with the Serum Institute of India.
A class-action lawsuit has been filed against the pharmaceutical company over allegations that its vaccine, co-developed with the University of Oxford, resulted in fatalities and severe injuries in numerous instances, The Telegraph reported.
The initial lawsuit was filed last year by Jamie Scott, a father of two, who suffered a permanent brain injury after experiencing a blood clot and brain hemorrhage following his vaccination in April 2021.
AstraZeneca is disputing the allegations but has acknowledged, in a legal filing submitted to the high court in February, that its Covid vaccine "can, in very rare cases, cause TTS" — Thrombosis with Thrombocytopenia Syndrome. TTS leads to blood-clot formation and a decrease in blood platelet count.
In a letter of response sent in May 2023, AstraZeneca informed Scott's lawyers that they do not accept the assertion that TTS is caused by the vaccine on a generic level.
However, in a legal document submitted to the high court in February, AstraZeneca said: "It is admitted that the AZ vaccine can, in very rare cases, cause TTS. The causal mechanism is not known."
"Further, TTS can also occur in the absence of the AZ vaccine (or any vaccine). Causation in any individual case will be a matter for expert evidence," it said.
-
We May Need Another Tukaram Mundhe To Fight Air Pollution | The Reason Why
Developers may install basic measures such as sprinklers and green nets, resume work, and continue violating rules when this equipment stops working.
-
Extracting Value From Battery Scrap Could Be Challenging For India | The Reason Why
A discarded lithium-ion battery still contains valuable materials such as lithium, nickel and cobalt. These can be recovered and reused. When such batteries are crushed and shredded, they produce a dark powder called black mass.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.